Incorporation of Molecularly Targeted Agents in the Primary Treatment of Squamous Cell Carcinomas of the Head and Neck

Hematology/Oncology Clinics of North America

Volumn 22, Issue 6, 2008, Pages 1193-1208

  Bernier, Jacques ^a  

^a Genolier Swiss Medical Network SA   (Switzerland)

Author keywords

Chemotherapy; Head and neck; Molecularly targeted agents; Radiotherapy; Squamous cell carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CEDIRANIB; CETUXIMAB; CIMAHER; CISPLATIN; CYTOSTATIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; HUMAX EGFR; LAPATINIB; NIMOTUZUMAB; PACLITAXEL; PANITUMUMAB; PLATINUM; TAXANE DERIVATIVE; THERACIM H R3; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN INHIBITOR; ZALUTUMUMAB;

ACNE; ADVANCED CANCER; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DERMATITIS; DRUG MECHANISM; DRUG TOLERABILITY; FISTULA; HEAD AND NECK CANCER; HUMAN; INJECTION SITE REACTION; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RASH; REVIEW; SKIN MANIFESTATION; SQUAMOUS CELL CARCINOMA; TISSUE NECROSIS; TREATMENT OUTCOME; ULCER; UNSPECIFIED SIDE EFFECT;

CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DRUG DELIVERY SYSTEMS; HEAD AND NECK NEOPLASMS; HUMANS; TUMOR MARKERS, BIOLOGICAL;

EID: 55849098900     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2008.08.003     Document Type: Review

References (69)

1. Parkin D.M., Bray F., Ferlay J., et al. Global cancer statistics, 2002. CA Cancer J Clin 55 2 (2005) 74-108
2. Vernham G.A., and Crowther J.A. Head and neck carcinoma-stage at presentation. Clin Otolaryngol Allied Sci 19 2 (1994) 120-124
3. Posner M.R., Hershock D.M., Blajman C.R., et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357 17 (2007) 1705-1715
4. Vermorken J.B., Remenar E., van Herpen C., et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357 17 (2007) 1695-1704
5. Calais G., Alfonsi M., Bardet E., et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 91 24 (1999) 2081-2086
6. Huguenin P., Beer K.T., Allal A., et al. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol 22 23 (2004) 4665-4673
7. Fu K.K., Pajak T.F., Trotti A., et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 48 1 (2000) 7-16
8. Bernier J., Domenge C., Ozsahin M., et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350 19 (2004) 1945-1952
9. Cooper J.S., Pajak T.F., Forastiere A.A., et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350 19 (2004) 1937-1944
10. Almadori G., Bussu F., and Paludetti G. Should there be more molecular staging of head and neck cancer to improve the choice of treatments and thereby improve survival?. Curr Opin Otolaryngol Head Neck Surg 16 2 (2008) 117-126
11. Perez-Ordonez B., Beauchemin M., and Jordan R.C. Molecular biology of squamous cell carcinoma of the head and neck. J Clin Pathol 59 5 (2006) 445-453
12. Lothaire P., de Azambuja E., Dequanter D., et al. Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation. Head Neck 28 3 (2006) 256-269
13. Waksal H.W. Role of an anti-epidermal growth factor receptor in treating cancer. Cancer Metastasis Rev 18 4 (1999) 427-436
14. Petersen C., Eicheler W., Frommel A., et al. Proliferation and micromilieu during fractionated irradiation of human FaDu squamous cell carcinoma in nude mice. Int J Radiat Biol 79 7 (2003) 469-477
15. Ang K.K., Berkey B.A., Tu X., et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62 24 (2002) 7350-7356
16. Magne N., Pivot X., Bensadoun R.J., et al. The relationship of epidermal growth factor receptor levels to the prognosis of unresectable pharyngeal cancer patients treated by chemo-radiotherapy. Eur J Cancer 37 17 (2001) 2169-2177
17. Eriksen J.G., Steiniche T., and Overgaard J. The influence of epidermal growth factor receptor and tumor differentiation on the response to accelerated radiotherapy of squamous cell carcinomas of the head and neck in the randomized DAHANCA 6 and 7 study. Radiother Oncol 74 2 (2005) 93-100
18. Bentzen S.M., Atasoy B.M., Daley F.M., et al. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol 23 24 (2005) 5560-5567
19. Hasegawa Y., Goto M., Hanai N., et al. Prediction of chemosensitivity using multigene analysis in head and neck squamous cell carcinoma. Oncology 73 1-2 (2007) 104-111
20. Teknos T.N., Cox C., Yoo S., et al. Elevated serum vascular endothelial growth factor and decreased survival in advanced laryngeal carcinoma. Head Neck 24 11 (2002) 1004-1011
21. Tse G.M., Chan A.W., Yu K.H., et al. Strong immunohistochemical expression of vascular endothelial growth factor predicts overall survival in head and neck squamous cell carcinoma. Ann Surg Oncol 14 12 (2007) 3558-3565
22. Brieger J., Kattwinkel J., Berres M., et al. Impact of vascular endothelial growth factor release on radiation resistance. Oncol Rep 18 6 (2007) 1597-1601
23. Ciardiello F., Troiani T., Bianco R., et al. Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy. Ann Oncol 17 Suppl 7 (2006) vii109-vii114
24. Michalides R.J., van Veelen N.M., Kristel P.M., et al. Overexpression of cyclin D1 indicates a poor prognosis in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 123 5 (1997) 497-502
25. Henriksson E., Baldetorp B., Borg A., et al. p53 mutation and cyclin D1 amplification correlate with cisplatin sensitivity in xenografted human squamous cell carcinomas from head and neck. Acta Oncol 45 3 (2006) 300-305
26. Wang M.B., Yip H.T., and Srivatsan E.S. Antisense cyclin D1 enhances sensitivity of head and neck cancer cells to cisplatin. Laryngoscope 111 6 (2001) 982-988
27. Kalish L.H., Kwong R.A., Cole I.E., et al. Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines. Clin Cancer Res 10 22 (2004) 7764-7774
28. Partridge M., Costea D.E., and Huang X. The changing face of p53 in head and neck cancer. Int J Oral Maxillofac Surg 36 12 (2007) 1123-1138
29. Geisler S.A., Olshan A.F., Weissler M.C., et al. p16 and p53 protein expression as prognostic indicators of survival and disease recurrence from head and neck cancer. Clin Cancer Res 8 11 (2002) 3445-3453
30. Lassaletta L., Brandariz J.A., Benito A., et al. p53 expression in locally advanced pharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 125 12 (1999) 1356-1359
31. Cabelguenne A., Blons H., de Waziers I., et al. p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. J Clin Oncol 18 7 (2000) 1465-1473
32. Poeta M.L., Manola J., Goldwasser M.A., et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med 357 25 (2007) 2552-2561
33. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 6 (2006) 567-578
34. Baselga J., Trigo J.M., Bourhis J., et al. Phase ll multicenter study of the anti-epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 23 (2005) 5568-5577
35. Burtness B., Goldwasser M.A., Flood W., et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 23 34 (2005) 8646-8654
36. Herbst R.S., Arquette M., Shin D.M., et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 23 24 (2005) 5578-5587
37. Curran D., Giralt J., Harari P.M., et al. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol 25 16 (2007) 2191-2197
38. Budach V.G., Stuschke M., Budach W., et al. Accelerated hyperfractionated chemoradiation (C-HART) plus 5-FU/MMC is superior to HART for inoperable locally advanced head and neck cancer. Final results of the German ARO 95-06 multicentre trial. J Clin Oncol 22 14S (2004) [Abstract 5503]
39. Semrau R., Mueller R.P., Stuetzer H., et al. Efficacy of intensified hyperfractionated and accelerated radiotherapy and concurrent chemotherapy with carboplatin and 5-fluorouracil: updated results of a randomized multicentric trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 64 5 (2006) 1308-1316
40. Caudell J.J., Sawrie S.M., Spencer S.A., et al. Locoregionally advanced head and neck cancer treated with primary radiotherapy: a comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment. Int J Radiat Oncol Biol Phys (2008) [E-pub]
41. Pfister D.G., Su Y.B., Kraus D.H., et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol 24 7 (2006) 1072-1078
42. Wanebo H.J., Ghebremichael M., Burtness B., et al. Phase II evaluation of cetuximab (C225) combined with induction paclitaxel and carboplatin followed by C225, paclitaxel, carboplatin, and radiation for stage III/IV operable squamous cancer of the head and neck (ECOG, E2303). J Clin Oncol 25 18S (2007) [Abstract 6015]
43. Argiris A., Karamouzis M.V., Heron D.E., et al. Phase II trial of docetaxel (T), cisplatin (P), and cetuximab (E) followed by concurrent radiation (RT), P, and E in locally advanced head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 25 18S (2007) [Abstract 6051]
44. Kuperman D.I., Nussenbaum B., Thorstad W., et al. Retrospective analysis of the addition of cetuximab to induction chemotherapy (IC) with docetaxel, cisplatin and 5-fluorouracil (TPF-C) for locally advanced squamous cell carcinoma of the head and neck (LA-HNSCC). J Clin Oncol 25 18S (2007). [Abstract 6072 and virtual presentation]. Available at: http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vm view=abst_detail_view&confID=47&abstractID=35471#
45. Wirth L.J., Posner M.R., Tishler R.B., et al. Phase I study of panitumumab, chemotherapy and intensity-modulated radiotherapy (IMRT) for head and neck cancer (HNC): early results. J Clin Oncol 25 18S (2007) [Abstract 6083]
46. Bastholt L., Specht L., Jensen K., et al. Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neck. Radiother Oncol 85 1 (2007) 24-28
47. Crombet T., Osorio M., Cruz T., et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 22 9 (2004) 1646-1654
48. Chen C., Kane M., Song J., et al. Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer. J Clin Oncol 25 31 (2007) 4880-4886
49. Morris J.C., Allen C.T., Citrin D., et al. Pilot phase I study of gefitinib (GEF) in combination with paclitaxel (PAC) and radiation therapy (RT) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC) and effects on epidermal growth factor receptor (EGFR) signaling pathway. J Clin Oncol 25 18S (2007) [Abstract 16526]
50. Rueda A., Medina J.A., Mesia R., et al. Gefitinib plus concomitant boost accelerated radiation (AFX-CB) and concurrent weekly cisplatin for locally advanced unresectable squamous cell head and neck carcinomas (SCCHN): a phase II study. J Clin Oncol 25 18S (2007) [Abstract 6031]
51. Doss H.H., Greco F.A., Meluch A.A., et al. Induction chemotherapy + gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients (pts) with locally advanced squamous carcinoma of the head and neck: a phase I/II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 24 18S (2006) [Abstract 5543]
52. Savvides P., Agarwala S.S., Greskovich J., et al. Phase I study of the EGFR tyrosine kinase inhibitor erlotinib in combination with docetaxel and radiation in locally advanced squamous cell cancer of the head and neck (SCCHN). J Clin Oncol 25 18S (2006) [Abstract 5545]
53. Herchenhorn D., Dias F.L., Pineda R.M., et al. Phase II study of erlotinib combined with cisplatin and radiotherapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 25 18S (2007) [Abstract 6033]
54. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 21 (2004) 2129-2139
55. Eberhard D.A., Johnson B.E., Amler L.C., et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23 25 (2005) 5900-5909
56. De Roock W., Piessevaux H., De Schutter J., et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19 3 (2008) 508-515
57. Amado R.G., Wolf M., Peeters M., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26 10 (2008) 1626-1634
58. Kelly K., Chansky K., Gaspar L.E., et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol (2008) [E-pub]
59. Cohen E.E., Lingen M.W., Martin L.E., et al. Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res 11 22 (2005) 8105-8108
60. Anderson J.A., Irish J.C., and Ngan B.Y. Prevalence of RAS oncogene mutation in head and neck carcinomas. J Otolaryngol 21 5 (1992) 321-326
61. Yarbrough W.G., Shores C., Witsell D.L., et al. Ras mutations and expression in head and neck squamous cell carcinomas. Laryngoscope 104 11 Pt 1 (1994) 1337-1347
62. Milas L., Fang F.M., Mason K.A., et al. Importance of maintenance therapy in C225-induced enhancement of tumor control by fractionated radiation. Int J Radiat Oncol Biol Phys 67 2 (2007) 568-572
63. Savvides P., Greskovich J., Bokar J., et al. Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell cancer of the head and neck (SCCHN). J Clin Oncol 25 18S (2007) [Abstract 6068]
64. Seiwert T.Y., Haraf D.J., Cohen E.E., et al. A phase I study of bevacizumab (B) with fluorouracil (F) and hydroxyurea (H) with concomitant radiotherapy (X) (B-FHX) for poor prognosis head and neck cancer (HNC). J Clin Oncol 24 18S (2007) [Abstract 5530]
65. Bozec A., Formento P., Lassalle S., et al. Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: antitumour supra-additive effects on human head and neck cancer xenografts. Br J Cancer 97 1 (2007) 65-72
66. Harrington K.J., Bourhis J., Nutting C.M., et al. A phase I, open-label study of lapatinib plus chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 24 18S (2006) [Abstract 5553]
67. Sano D., Kawakami M., Fujita K., et al. Antitumor effects of ZD6474 on head and neck squamous cell carcinoma. Oncol Rep 17 2 (2007) 289-295
68. Gustafson D.L., Frederick B., Merz A.L., et al. Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts. Cancer Chemother Pharmacol 61 2 (2008) 179-188
69. Van Waes C., Chang A.A., Lebowitz P.F., et al. Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 63 5 (2005) 1400-1412